On January 16, 2025, Huapu Biotechnology completed the company's change registration, the board of directors was adjusted, and Liu Yongjun was appointed as the chairman. This is also the first time that Liu Yongjun has clearly announced his new destination since leaving Shiyao Group in December last year.

Huapu Biotechnology was founded in 2001 and is located in Shijiazhuang, Hebei Province. Based on immunology, it focuses on the development of new drugs in the fields of tumors, infections, and autoimmune diseases. At present, a CpG technology platform has been established for the development of innovative vaccines, tumor immunotherapy, etc.

Liu Yongjun was established as a scientific founder at the beginning of the company, and another scientific founder was Professor Chen Jianzhu. Wang Xinzhong, the founder of Fushengkang, served as the global R&D president and chief scientist of the company after the merger was completed. The three R&D experts are all senior experts in the field of immunology.

Huapu Biotechnology has two innovative drugs entering the clinical stage, including CpG ODN immune agonist HP007 and bifunctional antibody fusion protein FS-8002.

Source: https://pharm.jgvogel.cn/c1484173.shtml